FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Fampridine-SR is registered for the treatment of walking incapacity in MS patients. Two
pivotal trials show that app. 40% of MS patients with walking incapacity can improve walking
speed averagely 25% when recieving the drug. This has been shown using the Timed 25 Foot Walk
Test (T25FW). No effect on cognition and upper limb function has been shown, but this has not
been investigated in patients responding to the drug measured by the abovementioned test.
The question is if this will be the case and also if another walking test, termed the Six
Spot Step Test (SSST), will be more sensitive to the effect of Fampridine-SR.
Primary outcome measure is the effect measured by SSST. The hypothesis is that SSST is not
less sensitive to the effect of Fampridine-SR than T25FW.